are looking at
Diabetes comprises a collection of metabolic disorders in which chronic hyperglycaemia arises as a result of insulin deficiency, insulin resistance, or a combination of the two.
There are three main types of diabetes. The most common, Type 2 diabetes, is often secondary to weight gain and involves impaired insulin secretion and the development of insulin resistance.
Type 1 diabetes is characterised by absolute insulin deficiency resulting from autoimmune destruction of the β-cells of the pancreas.
Gestational diabetes occurs when the pancreas fails to produce sufficient insulin to compensate for the state of increased insulin resistance that occurs during pregnancy.
Symptoms of diabetes include polyuria, thirst, infections and blurred vision, with suspected cases confirmed using blood tests.
Long-term diabetes is associated with various microvascular complications including retinopathy and nephropathy, as well as macrovascular disease, so effective treatment to normalise blood glucose levels is vital. While patients with type 1 diabetes require treatment with insulin, early type 2 diabetes can often be managed through lifestyle modifications, although glucose lowering agents may be required, particularly as the disease progresses.
To find out more about Type 2 diabetes, visit our dedicated Cardiovascular Metabolism Learning Zone which includes further information regarding the epidemiology and management for this condition.
Related news and insights
Novo Nordisk announced headline results from the PIONEER PLUS trial, a phase IIIb, 68-week, efficacy and safety trial with once-daily oral semaglutide 25 mg and 50 mg versus 14 mg as add-on to a stable dose of 1–3 oral antidiabetic medicines in people with type 2 diabetes in need of treatment intensification .
Oculis S.A., announces the completion of enrollment for stage 1 of its Phase III DIAMOND (DIAbetic Macular edema patients ON a Drop) study evaluating the efficacy and safety of OCS 01 in ppatients with diabetic macular edema (DME)
Boehringer Ingelheim and Eli Lilly and Company announced that the FDA accepted a supplemental New Drug Application (sNDA) for Jardiance (empagliflozin) investigating a potential new indication to lower blood sugar along with diet and exercise in children 10 years and older with type 2 diabetes.